Jane Street Group LLC Has $542,000 Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jane Street Group LLC lessened its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 47.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 340,840 shares of the company's stock after selling 309,120 shares during the period. Jane Street Group LLC owned about 0.38% of Caribou Biosciences worth $542,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its stake in Caribou Biosciences by 28.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company's stock valued at $57,000 after buying an additional 8,008 shares during the period. Milestone Asset Management LLC lifted its position in shares of Caribou Biosciences by 5.6% in the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company's stock valued at $260,000 after buying an additional 8,662 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after buying an additional 9,148 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Caribou Biosciences by 9.2% in the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after buying an additional 13,421 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Caribou Biosciences by 43.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock valued at $74,000 after buying an additional 14,021 shares during the last quarter. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Down 8.0%

Shares of Caribou Biosciences stock traded down $0.09 on Monday, hitting $0.97. The stock had a trading volume of 2,427,298 shares, compared to its average volume of 1,458,007. Caribou Biosciences, Inc. has a twelve month low of $0.66 and a twelve month high of $3.00. The business's 50 day moving average is $0.88 and its two-hundred day moving average is $1.31. The stock has a market cap of $90.67 million, a price-to-earnings ratio of -0.59 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.35 million for the quarter, compared to the consensus estimate of $1.48 million. As a group, equities analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Four research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $7.40.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.